|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sternberg CN, Yagoda A, Scher HI, Watson
RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani
PC, et al: Preliminary results of M-VAC (methotrexate, vinblastine,
doxorubicin and cisplatin) for transitional cell carcinoma of the
urothelium. J Urol. 133:403–407. 1985.PubMed/NCBI
|
|
3
|
Loehrer PJ Sr, Einhorn LH, Elson PJ,
Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R,
Sarosdy MF, Lowe BA, et al: A randomized comparison of cisplatin
alone or in combination with methotrexate, vinblastine, and
doxorubicin in patients with metastatic urothelial carcinoma: A
cooperative group study. J Clin Oncol. 10:1066–1073.
1992.PubMed/NCBI
|
|
4
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol. 18:3068–3077.
2000.PubMed/NCBI
|
|
5
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yafi FA, North S and Kassouf W: First- and
second-line therapy for metastatic urothelial carcinoma of the
bladder. Curr Oncol. 18:e25–e34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Feldman BJ and Feldman D: The development
of androgenindependent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View
Article : Google Scholar
|
|
8
|
Chia K, O'Brien M, Brown M and Lim E:
Targeting the androgen receptor in breast cancer. Curr Oncol Rep.
17:42015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ha YS, Lee GT, Modi P, Kwon YS, Ahn H, Kim
WJ and Kim IY: Increased expression of androgen receptor mRNA in
human renal cell carcinoma cells is associated with poor prognosis
in patients with localized renal cell carcinoma. J Urol.
194:1441–1448. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma WL, Lai HC, Yeh S, Cai X and Chang C:
Androgen receptor roles in hepatocellular carcinoma, fatty liver,
cirrhosis and hepatitis. Endocr Relat Cancer. 21:R165–R182. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mikkonen L, Pihlajamaa P, Sahu B, Zhang FP
and Jänne OA: Androgen receptor and androgen-dependent gene
expression in lung. Mol Cell Endocrinol. 317:14–24. 2010.
View Article : Google Scholar
|
|
12
|
Wu JT, Han BM, Yu SQ, Wang HP and Xia SJ:
Androgen receptor is a potential therapeutic target for bladder
cancer. Urology. 75:820–827. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shiota M, Takeuchi A, Yokomizo A,
Kashiwagi E, Tatsugami K, Kuroiwa K and Naito S: Androgen receptor
signaling regulates cell growth and vulnerability to doxorubicin in
bladder cancer. J Urol. 188:276–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Siddique HR, Mishra SK, Karnes RJ and
Saleem M: Lupeol, a novel androgen receptor inhibitor: Implications
in prostate cancer therapy. Clin Cancer Res. 17:5379–5391. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Izumi K and Miyamoto H: The role of
the androgen receptor in the development and progression of bladder
cancer. Jpn J Clin Oncol. 42:569–577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Y, Clegg NJ and Scher HI:
Anti-androgens and androgen-depleting therapies in prostate cancer:
New agents for an established target. Lancet Oncol. 10:981–991.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tran C, Ouk S, Clegg NJ, Chen Y, Watson
PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, et al:
Development of a second-generation antiandrogen for treatment of
advanced prostate cancer. Science. 324:787–790. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jeon HG, Yoon CY, Yu JH, Park MJ, Lee JE,
Jeong SJ, Hong SK, Byun SS and Lee SE: Induction of caspase
mediated apoptosis and down-regulation of nuclear factor-κB and Akt
signaling are involved in the synergistic antitumor effect of
gemcitabine and the histone deacetylase inhibitor trichostatin A in
human bladder cancer cells. J Urol. 186:2084–2093. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miyamoto H, Yang Z, Chen YT, Ishiguro H,
Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, et al:
Promotion of bladder cancer development and progression by androgen
receptor signals. J Natl Cancer Inst. 99:558–568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: RNA interference targeting the M2 subunit of
ribonucleotide reductase enhances pancreatic adenocarcinoma
chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004.
View Article : Google Scholar
|
|
22
|
Giovannetti E, Del Tacca M, Mey V, Funel
N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro
M, et al: Transcription analysis of human equilibrative nucleoside
transporter-1 predicts survival in pancreas cancer patients treated
with gemcitabine. Cancer Res. 66:3928–3935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakahira S, Nakamori S, Tsujie M,
Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa
I, Miyamoto A, et al: Involvement of ribonucleotide reductase M1
subunit overexpression in gemcitabine resistance of human
pancreatic cancer. Int J Cancer. 120:1355–1363. 2007. View Article : Google Scholar
|
|
24
|
Ohhashi S, Ohuchida K, Mizumoto K, Fujita
H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E and Tanaka M:
Down-regulation of deoxycytidine kinase enhances acquired
resistance to gemcitabine in pancreatic cancer. Anticancer Res.
28B:2205–2212. 2008.
|
|
25
|
Skrypek N, Duchêne B, Hebbar M, Leteurtre
E, van Seuningen I and Jonckheere N: The MUC4 mucin mediates
gemcitabine resistance of human pancreatic cancer cells via the
concentrative nucleoside transporter family. Oncogene.
32:1714–1723. 2013. View Article : Google Scholar
|
|
26
|
Harris WP, Mostaghel EA, Nelson PS and
Montgomery B: Androgen deprivation therapy: Progress in
understanding mechanisms of resistance and optimizing androgen
depletion. Nat Clin Pract Urol. 6:76–85. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tombal B: What is the pathophysiology of a
hormone-resistant prostate tumour? Eur J Cancer. 47(Suppl 3):
S179–S188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thadani-Mulero M, Portella L, Sun S, Sung
M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR and
Giannakakou P: Androgen receptor splice variants determine taxane
sensitivity in prostate cancer. Cancer Res. 74:2270–2282. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen L, Chang WC, Hung YC, Chang YY, Bao
BY, Huang HC, Chung WM, Shyr CR and Ma WL: Androgen receptor
increases CD133 expression and progenitor-like population that
associate with cisplatin resistance in endometrial cancer cell
line. Reprod Sci. 21:386–394. 2014. View Article : Google Scholar :
|
|
30
|
Sun NK, Huang SL, Lu HP, Chang TC and Chao
CC: Integrative transcriptomics-based identification of cryptic
drivers of taxol-resistance genes in ovarian carcinoma cells:
Analysis of the androgen receptor. Oncotarget. 6:27065–27082. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Izumi K, Taguri M, Miyamoto H, Hara Y,
Kishida T, Chiba K, Murai T, Hirai K, Suzuki K, Fujinami K, et al:
Androgen deprivation therapy prevents bladder cancer recurrence.
Oncotarget. 5:12665–12674. 2014. View Article : Google Scholar
|
|
32
|
Mashhadi R, Pourmand G, Kosari F, Mehrsai
A, Salem S, Pourmand MR, Alatab S, Khonsari M, Heydari F, Beladi L,
et al: Role of steroid hormone receptors in formation and
progression of bladder carcinoma: A case-control study. Urol J.
11:1968–1973. 2014.PubMed/NCBI
|
|
33
|
Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu
I, Izumi K, Chang C, Messing EM, Netto GJ and Yeh S: Expression of
androgen and oestrogen receptors and its prognostic significance in
urothelial neoplasm of the urinary bladder. BJU Int. 109:1716–1726.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kashiwagi E, Ide H, Inoue S, Kawahara T,
Zheng Y, Reis LO, Baras AS and Miyamoto H: Androgen receptor
activity modulates responses to cisplatin treatment in bladder
cancer. Oncotarget. Jun 14–2016.Epub ahead of print. View Article : Google Scholar
|
|
35
|
Kawahara T, Ide H, Kashiwagi E,
El-Shishtawy KA, Li Y, Reis LO, Zheng Y and Miyamoto H:
Enzalutamide inhibits androgen receptor-positive bladder cancer
cell growth. Urol Oncol. 34:432.e15–23. 2016. View Article : Google Scholar
|
